Publications by authors named "Barbara Formisano"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

152,304

Total Likes

7,982

Extended Reach

192,501

Social Features

13
A
Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial.
Francesca Ligorio, Riccardo Lobefaro, Giovanni Fucà, Leonardo Provenzano, Lucrezia Zanenga, Vincenzo Nasca, Caterina Sposetti, Giulia Salvadori, Angela Ficchì, Andrea Franza

January 2024

Videos about Article: user user

2 1 10

View All Article and Social Media Activity
T
The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis.
Leonardo Provenzano, Riccardo Lobefaro, Francesca Ligorio, Emma Zattarin, Luca Zambelli, Barbara Formisano

Ther Adv Med Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies.
Sara Pusceddu, Filippo De Braud, Giuseppe Lo Russo, Laura Concas, Daniela Femia, Barbara Formisano

Oncotarget· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes.
Sara Pusceddu, Roberto Buzzoni, Claudio Vernieri, Laura Concas, Sara Marceglia, Barbara Formisano

Future Oncol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review.
Sara Pusceddu, Filippo De Braud, Fabrizio Festinese, Cristina Bregant, Alice Lorenzoni, Barbara Formisano

Future Oncol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.
Sara Pusceddu, Filippo de Braud, Laura Concas, Cristina Bregant, Livia Leuzzi, Barbara Formisano

Tumori· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study.
Emilio Bajetta, Filippo Pietrantonio, Roberto Buzzoni, Erminia Ferrario, Francesca Valvo, Barbara Formisano

Am J Clin Oncol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen.
Filippo Pietrantonio, Pamela Biondani, Filippo de Braud, Alessandro Pellegrinelli, Giampaolo Bianchini, Barbara Formisano

Transl Oncol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuroendocrine tumors of unknown primary site: gold dust or misdiagnosed neoplasms?
Laura Catena, Ettore Bichisao, Massimo Milione, Monica Valente, Marco Platania, Barbara Formisano

Tumori· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A literature overview of primary cervical malignant melanoma: an exceedingly rare cancer.
Sara Pusceddu, Emilio Bajetta, Maria Luisa Carcangiu, Barbara Formisano, Monika Ducceschi

Crit Rev Oncol Hematol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer.
Marco Platania, Francesco Agustoni, Barbara Formisano, Milena Vitali, Monika Ducceschi

Target Oncol· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Common Diagnostic Challenges in the Histopathologic Diagnosis of Neuroendocrine Lung Tumors: A Case Report.
Monica Valente, Laura Catena, Massimo Milione, Sara Pusceddu, Barbara Formisano

Case Rep Oncol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pitfalls in the diagnosis of neuroendocrine tumors: atypical clinical and radiological findings as cause of medical mistakes.
Emilio Bajetta, Laura Catena, Monika Ducceschi, Sara Pusceddu, Massimo Milione, Barbara Formisano

Tumori· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
Emilio Bajetta, Laura Catena, Giuseppe Procopio, Sara De Dosso, Ettore Bichisao, Barbara Formisano

Cancer Chemother Pharmacol· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer.
Paolo Bidoli, Simonetta C Stani, Luigi Mariani, Daniela De Candis, Diego Cortinovis, Barbara Formisano

Lung Cancer· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis